Industry Symposia

#WCLC19

Get Tickets!

Industry Symposia are programs held at the IASLC 2019 World Conference on Lung Cancer (IASLC WCLC 2019), are not sponsored or endorsed by the IASLC and are not part of the official IASLC accredited program.

Click on the session titles below to read more about each program.

September 07
September 08
September 09
September 10

Time: 9:45 - 11:15 | Location: Hall 8.0, Copenhagen (1980)

IS01 - Symposium by Bayer Healthcare Pharmaceuticals: Precision Medicine: Optimizing The Approach To Lung Cancer Through Testing (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Silvia Novello, Italy, Anna Farago, USA, Lukas Heukamp, Germany

Agenda

Time	Presentation
09:45	Welcome and Introduction Silvia Novello, Italy
Part 1: Genomic Testing in Lung Cancer: Ask The Experts
09:55	The Pathologist’s Perspective Lukas Heukamp, Germany
10:10	The Oncologist’s Perspective Silvia Novello, Italy
10:25	Panel Discussion and Q&A All
Part 2: The Multidisciplinary Team in Action
10:40	Meet the Patients Anna Farago, USA
11:00	Panel Discussion and Q&A All

Time: 11:30 - 13:00 | Location: Hall 8.0, Hilton Head (1978)

IS02 - Symposium by Ology Medical Education: Spotlight On Emerging Immunotherapy Approaches And MET Inhibitors In Advanced NSCLC (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Everett Vokes, USA, Luis Paz-Ares, Spain, Ross Camidge, USA, Martin Reck, Germany

Time	Presentation
11:30	Welcome and Introduction Everett Vokes, USA
11:40	What is the Current Clinical Status of Novel Immunotherapies in Advanced NSCLC? Luis Paz-Ares, Spain
12:05	What Does the Latest Evidence Reveal for Emerging MET Inhibitors? Ross Camidge, USA
12:30	Are We Optimally Prepared to Provide Personalized Treatment Strategies? Martin Reck, Germany
12:55	Summary and Adjournment

Time: 13:00 - 14:30 | Location: Hall 8.0, Copenhagen (1980)

IS03 - Symposium by Takeda Oncology: Current Treatment Landscape And Unmet Needs In ALK+ NSCLC (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Pilar Garrido, Spain, Pasi Janne, USA, Sanjay Popat, UK

Agenda

Time	Presentation
13:00	Welcome and Introductions Pilar Garrido, Spain
13:05	Insights Into Resistance Mechanisms in ALK+ NSCLC Pasi A. Jänne, USA
13:25	Current Treatment Landscape in ALK+ NSCLC Sanjay Popat, United Kingdom
13:45	Long-term Safety, Tolerability, and Quality of Life with ALK Inhibitors Pilar Garrido, Spain
14:05	Panel Discussion of a Patient Case Study and Q&A Faculty
14:25	Closing Remarks Pilar Garrido, Spain

Time: 14:30 - 16:00 | Location: Hall 8, Vancouver (2003)

IS04 - Symposium by Bristol-Myers Squibb: Point/Counterpoint: Maximizing the Impact of I-O Across NSCLC (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Scott Antonia, USA, Natasha Leighl, Canada, Antonio Calles, Spain

Agenda

Time	Presentation
14:30	Welcome and Introductions Scott Antonia, USA
14:35	Timing of I-O Treatment in Early-Stage NSCLC Moderator: Natasha Leighl, Canada Scott Antonia, USA vs Antonio Calles, Spain
15:00	I-O + Chemotherapy vs Non-Chemotherapy I-O Options in 1L mNSCLC Moderator: Scott Antonia, USA Antonio Calles, Spain vs Natasha Leighl, Canada
15:25	2L Treatment in an Evolving Landscape: Exploring I-O vs Non–I-O Treatment Options Moderator: Antonio Calles, Spain Natasha Leighl, Canada vs Scott Antonia, USA
15:50	Closing Remarks and Audience Q&A Scott Antonia, USA

Time: 16:00 - 17:30 | Location: Hall 8, Copenhagen (1980)

IS05 - Symposium by Springer Healthcare: Simplifying The Sequencing Of Treatment In NSCLC Patients With No Actionable Mutations (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Corey Langer, USA, Enriqueta Felip, Spain, David Heigener, Germany, Myung-Ju Ahn, Korea

Agenda

Time	Presentation
16:00	Welcome and Introduction Corey Langer, USA
16:10	Where Should We Begin? Enriqueta Felip, Spain
16:35	Navigating the Increasingly Complex Second-line Setting David Heigener, Germany
17:00	Special Considerations for Hyperprogressive Disease Myung-Ju Ahn, Korea
17:15	Panel and Audience Discussion: Bridging the Gap Between Promise and Reality All Speakers
17:25	Close Corey Langer, USA

Time: 7:00 - 8:00 | Location: Hall 8.0, Copenhagen (1980)

IS06 - Symposium by F. Hoffmann-La Roche: How Immunotherapy Is Continuing To Revolutionise First-Line Lung Cancer Care (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Ross Soo, Singapore, Thomas Newsom-Davis, UK, Fabrice Barlesi, France

Agenda

Time	Presentation
07:00	Welcome and Introduction Ross Soo, Singapore
07:10	Non-squamous NSCLC: Continuing to Address the Unmet Need Thomas Newsom-Davis, UK
07:30	SCLC: Towards a New Standard of Care Fabrice Barlesi, France
07:45	Will the Revolution Continue? Audience questions: All faculty
07:55	Summary and Close Ross Soo, Singapore

TIme: 7:00 - 8:00 | Location: Hall 8.0, Hilton Head (1978)

IS07 - Symposium by Daiichi Sankyo: Targeting Her Pathways In Advanced NSCLC: Emerging Concepts And Future Opportunities (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Frances Shepherd, Canada, Suresh Ramalingam, USA, Egbert Smit, Netherlands

Agenda

Time	Presentation
07:00	Welcome and Introduction Targeting HER2 Pathways in Oncogene Driven Advanced NSCLC: The Continuing Evolution of Personalised Treatment Frances Shepherd, Canada
07:10	The Role of Antibody Drug Conjugates (ADCs) in Thoracic Cancer: Current State-of-the-Art Suresh Ramalingam, USA
07:30	Targeting HER Pathways in Advanced NSCLC: Emerging Data and Future Prospects Egbert Smit, Netherlands
07:50	Q&A: Audience & Wrap-Up All Faculty Members

Time: 7:00 - 8:00 | Location: Hall 8.0, Vienna (2016)

IS08 - Symposium by Pfizer: EGFR+ and ALK+ NSCLC: More Options, Right Choices (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Nicolas Girard, France, Daniel Tan, Singapore, Alice Shaw, USA

Agenda

Time	Presentation
07:00	Welcome and Introduction Nicolas Girard, France
07:05	More Options, Right Choices Nicolas Girard, France
07:15	EGFR: The Dilemma of Choice Daniel Tan, Singapore
07:35	ALK: Sequencing Our Options to Maximise Outcomes Alice Shaw, USA
07:50	Panel Discussion All faculty, facilitated by Nicolas Girard, France

Time: 12:00 - 13:30 | Location: Hall 6, Barcelona (2005)

IS09 - Symposium by Physicians' Education Resource, LLC (PER): Leveraging The Lung Cancer Team In Stage III NSCLC With Immuno-Oncology Strategies (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Naiyer A. Rizvi, USA, Suresh Senan, Netherlands, Keith Kerr, United Kingdom, Rolf Stahel, Switzerland

Agenda

Time	Presentation
12:00	Welcome, Introductions, Pre-session Survey Naiyer A. Rizvi, USA
12:10	Assessing Treatment Standards for Patients with Unresectable Stage III NSCLC Rolf A. Stahel, Switzerland
12:25	Medical Crossfire® #1: Applying the Data to Patients with Stage III NSCLC Moderator: Naiyer A. Rizvi, USA Keith M. Kerr, United Kingdom Suresh Senan, Netherlands Rolf A. Stahel, Switzerland
12:40	Medical Crossfire® #2: Practical Concepts and Best Practices with Novel Immunotherapies for Management of Immune- Related Adverse Events Moderator: Naiyer A. Rizvi, USA Keith M. Kerr, United Kingdom Suresh Senan, Netherlands Rolf A. Stahel, Switzerland
13:00	Medical Crossfire® #3: Future Applications for Immunotherapy in Stage I-III NSCLC Moderator: Naiyer A. Rizvi, USA Faculty: Keith M. Kerr, United Kingdom Suresh Senan, Netherlands Rolf A. Stahel, Switzerland
13:15	Postsession Survey Naiyer A. Rizvi, USA
13:20	Question-and-Answer Session/Panel Discussion
13:30	Adjourn Naiyer A. Rizvi, USA

Time: 18:00 - 19:30 | Location: Hall 8.0, Hilton Head (1978)

IS10 - Symposium by Boehringer Ingelheim: Treatment Sequencing For Advanced NSCLC (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Tetsuya Mitsudomi, Japan, Keunchil Park, South Korea, Martin Schuler, Germany, David Gandara, USA, Nick Pavlakis, Australia

Agenda

Time	Presentation
18:00	Meeting Welcome and Introductions Tetsuya Mitsudomi, Japan
18:05	Maximising Time on EGFR TKI Therapy Keunchil Park, South Korea
18:20	Uncommon but Not Unknown: Efficacy of EGFR TKIs for Uncommon Mutations Martin Schuler, Germany
18:35	Panel Discussion: First-Line Treatment Considerations for EGFR-Mutated NSCLC Moderator: Tetsuya Mitsudomi, Japan
18:45	The Role of EGFR TKIs in the Treatment of Squamous NSCLC David Gandara, USA
19:00	NSCLC (Adenocarcinoma): The Role of Anti-Angiogenic Therapy in Overcoming Resistance to Immunotherapy Nick Pavlakis, Australia
19:15	Panel Discussion: Second-Line Treatment Considerations for Advanced NSCLC Moderator: Tetsuya Mitsudomi, Japan
19:25	Meeting Close Tetsuya Mitsudomi, Japan

Time: 7:00 - 8:00 | Location: Hall 8.0, Copenhagen (1980)

IS11 - Symposium by F. Hoffmann-La Roche: Waking Up To Precision Medicine In NSCLC (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Solange Peters, Switzerland, Nir Peled, Israel, Robert Doebele, USA

Agenda

Time	Presentation
07:00	Welcome Solange Peters, Switzerland
07:05	Comprehensive Genomic Profiling: The Future is Now Nir Peled, Israel
07:15	Leading the Way with ALK Solange Peters, Switzerland
07:25	Advancing Patient Care with TRK and ROS1 Robert Doebele, USA
07:35	Faculty Discussion and Q&A
07:55	Close Solange Peters, Switzerland

Time: 7:00 - 8:00 | Location: Hall 8.0, Hilton Head (1978)

IS12 - Symposium by Medscape: Expanding the Therapeutic Landscape Of Advanced NSCLC Targeting HER2 (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Hossein Borghaei, USA, Maurice Perol, France, Shirish Gadgeel, USA

Agenda

Time	Presentation
07:00	Welcome and Introduction Maurice Perol, France
07:05	When and How Can HER2 Be Tested in Patients with Advanced NSCLC? Maurice Perol, France
07:20	Case Discussion: NSCLC with HER2 Alteration Hossein Borghaei, USA
07:35	Future Therapeutic Landscape for HER2 Dysregulation Shirish Gadgeel, USA
07:50	Panel Discussion and Audience Questions All Faculty
08:00	Adjournment

Time: 7:00 - 8:00 | Location: Hall 8.0, Vienna (2016)

IS13 - Symposium by Illumina: Benefiting Lung Cancer Patients with Comprehensive Genomic Profiling (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: David Eberhard, USA, Ahmet Zehir, USA, Sandip Patel, USA

Agenda

Time	Presentation
07:00	Introduction Sandip Patel, USA
07:10	Transforming Oncology with Comprehensive Genomic Profiling David Eberhard, USA
07:25	Diagnostic and Clinical Utility of Common to Rare Fusions in Lung Cancer Ahmet Zehir, USA
07:50	Q&A

Time: 12:30 - 14:00 | Location: Hall 6, Barcelona (2005)

IS14 - Symposium by PeerVoice: Paving The Way To Better Outcomes In EGFR-Mutant NSCLC: Time To Take A Step Further? (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Lecia V. Sequist, USA, David Planchard, France, James Chih-Hsin Yang, Taiwan

Agenda

Time	Presentation
12:30	Welcome and Introduction Lecia V. Sequist, MD, MPH
12:35	Measuring Success of EGFR-Targeted Therapies: What’s the End Goal David Planchard, MD, PhD
12:55	Case Discussion: What Does Improved Survival Mean for Patients? Lecia V. Sequist, MD, MPH & Panel
13:10	Sequencing Therapies in EGFR-mutant NSCLC: Does Order Matter? James Chih-Hsin Yang, MD, PhD
13:30	Case Discussion: Strategies for Improving Long-Term Outcomes Lecia V. Sequist, MD, MPH & Panel
13:45	Q&A and Conclusions Lecia V. Sequist, MD, MPH & Panel

Time: 18:15 - 19:45 | Location: Hall 8.0, Hilton Head (1978)

IS15 - Symposium by Medscape: Immune Checkpoint Inhibitor Treatment for Frontline Metastatic NSCLC: The Evolving Role of Biomarkers in Guiding Decisions (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Heather Wakelee, USA, Raffaele Califano, UK, Wilfried Eberhardt, Germany, Marina Garassino, Italy

Agenda

Time	Presentation
18:15	Welcome and Introduction Heather Wakelee, USA
18:20	Immune Checkpoint Inhibitor Treatment Regimens in Frontline Metastatic NSCLC: Where Are We Now? Heather Wakelee, USA
18:30	The Role of PD-L1 Expression in Guiding Decisions: Analyzing the Current Evidence Raffaele Califano, United Kingdom
18:50	The Role of Tumor Mutational Burden (TMB) in Guiding Decisions: What Are We Learning From the Clinical Trial Data? Wilfried Eberhardt, Germany
19:10	Moving to Better Biomarker Guidance for ICI Therapies: Current and Future Outlook Marina Garassino, Italy
19:25	Panel Discussion All Faculty, moderated by Heather Wakalee, USA
19:40	Concluding Remarks Heather Wakelee, USA

Time: 7:00 - 8:00 | Location: Hall 8.0, Hilton Head (1978)

IS16 - Symposium by Novartis: The Road Ahead: New Horizons In The Treatment Of NSCLC (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Jürgen Wolf, Germany, Tony Mok, Hong Kong, David Spigel, USA

Agenda

Time	Presentation
07:00	Welcome and Introduction: Recent Advances in NSCLC Treatment Jürgen Wolf, Germany
07:10	Emerging New Targets for NSCLC Tony Mok, Hong Kong
07:30	Shaping the Future: Targeting Inflammation Beyond Checkpoint Inhibition David Spigel, USA
07:55	Closing Jürgen Wolf, Germany

Time: 7:00 - 8:00 | Location: Hall 6, Barcelona (2005)

IS17 - Symposium by MSD: Prioritizing Lung Cancer: Strengthening Public Policy Responses To Unmet Needs (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Georg Pall, Austria, Stefania Vallone, Italy, Mary Bussell, UK, Christian Sellars, USA

Agenda

Time	Presentation
07:00	Welcome and Introduction
07:05	The Global Lung Cancer Policy Landscape
07:15	Case Studies of National Lung Cancer Policy
07:25	Moderated Panel Discussion
07:45	Q&A
07:55	Closing Remarks

Time: 13:00 - 14:30 | Location: Hall 6, Barcelona (2005)

IS18 - Symposium by MSD: Redefining Survival Expectations In Lung Cancer (Not IASLC CME Accredited)

View Program / Invitation (PDF)

Chairs/Speakers: Johan Vansteenkiste, Belgium, Benjamin Levy, USA, Stephen Liu, USA

Agenda

Time	Presentation
13:00	Welcome and Introduction Johan Vansteenkiste, Belgium
13:05	Scientific Rationale for Combining Immune Check Point Inhibitors and Chemotherapy Johan Vansteenkiste, Belgium
13:20	Role of IO in mNSCLC Pro – Use of IO/Chemotherapy Combinations or Monotherapy in 1L Con – Preserve Option of IO Use for 2nd Line Stephen Liu, USA – Pro Ben Levy, USA – Con
13:50	Patient Cases Ben Levy, USA
14:05	Beyond NSCLC – SCLC, Mesothelioma Stephen Liu, USA
14:20	Q&A
14:30	Closing Remarks Johan Vansteenkiste, Belgium

Industry Symposia Guidelines

Are you a sponsor of an Industry Symposia? To access the ISS guidelines please click here. Please note this page is password protected and contains information for sponsors of Industry Symposia sessions only. The password has been provided to the main contacts associated with each symposium. If you are a sponsor of an Industry Symposia and require assistance accessing the guidelines please contact wclc2019-industry at icsevents.com.